ALBT vs. GMDAQ, ELOX, GMDA, KRBP, TCON, SQZ, FNCH, TCBP, SCNI, and ACOR
Should you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include Gamida Cell (GMDAQ), Eloxx Pharmaceuticals (ELOX), Gamida Cell (GMDA), Kiromic BioPharma (KRBP), TRACON Pharmaceuticals (TCON), SQZ Biotechnologies (SQZ), Finch Therapeutics Group (FNCH), TC Biopharm (TCBP), Scinai Immunotherapeutics (SCNI), and Acorda Therapeutics (ACOR). These companies are all part of the "biological products, except diagnostic" industry.
Avalon GloboCare (NASDAQ:ALBT) and Gamida Cell (NASDAQ:GMDAQ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation, earnings and community ranking.
Avalon GloboCare has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Gamida Cell has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.
1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 50.3% of Gamida Cell shares are held by institutional investors. 64.0% of Avalon GloboCare shares are held by insiders. Comparatively, 6.7% of Gamida Cell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Avalon GloboCare had 5 more articles in the media than Gamida Cell. MarketBeat recorded 5 mentions for Avalon GloboCare and 0 mentions for Gamida Cell. Avalon GloboCare's average media sentiment score of 0.25 beat Gamida Cell's score of 0.00 indicating that Avalon GloboCare is being referred to more favorably in the media.
Avalon GloboCare has higher earnings, but lower revenue than Gamida Cell. Avalon GloboCare is trading at a lower price-to-earnings ratio than Gamida Cell, indicating that it is currently the more affordable of the two stocks.
Gamida Cell has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,304.14%.
Avalon GloboCare and Gamida Cell both received 0 outperform votes by MarketBeat users.
Summary
Gamida Cell beats Avalon GloboCare on 7 of the 12 factors compared between the two stocks.
Get Avalon GloboCare News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avalon GloboCare Competitors List
Related Companies and Tools
